Phacilitate Leaders World

Conference speakers

Vijay Chiruvulu

Dr Vijay Chiruvulu

VP of Global Process Development - Cell Therapy, Kite Pharma (A Gilead Company)

Dr. Vijay Chiruvolu has had close to 22 years of biopharmaceutical industry experience in process development, manufacturing, risk management and Quality.  Currently, Dr. Chiruvolu is Vice President of Process Development at Kite Pharma, a Gilead Sciences Company, responsible for process design, tech transfer, process automation, analytical development, validation and manufacturing support of T-cell therapy processes.  Before joining Kite Pharma in 2014, Dr. Chiruvolu worked as Director of Corporate Quality at Amgen. As network leader, he provided strategic direction to Amgen sites in the areas of equipment, sterilization, cleaning, process, and packaging and transportation validations.  Previously Dr. Chiruvolu was the Director of Risk Management and was responsible for implementing ICHQ9, risk modeling and training of risk facilitators.  He also was the Director of Process Engineering providing manufacturing support of upstream and downstream processes.

Dr. Chiruvolu holds a PhD in biochemical engineering and an MBA.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman